This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.

开始日期2023-12-15

申办/合作机构

Queens Medical Center

NCT04553068

/ Completed临床3期

Phase 3 Double-blind Placebo-controlled Efficacy Trial of EVO100 Vaginal Gel for the Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection

开始日期2020-10-15

申办/合作机构

Evofem, Inc.

NCT03107377

/ Completed临床2/3期

Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection

Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection

开始日期2017-11-03

申办/合作机构

Evofem, Inc.

[+1]

100 项与 L-乳酸/柠檬酸/酒石酸氢钾相关的临床结果

登录后查看更多信息

100 项与 L-乳酸/柠檬酸/酒石酸氢钾相关的转化医学

登录后查看更多信息

100 项与 L-乳酸/柠檬酸/酒石酸氢钾相关的专利（医药）

登录后查看更多信息

项与 L-乳酸/柠檬酸/酒石酸氢钾相关的文献（医药）

2026-06-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Development of a pH-modulating vaginal film through direct powder extrusion 3D printing for on-demand, hormone-free contraception: a quality by design approach

Article

作者: Repka, Michael A ; Baisa, Srikanth ; Vemula, Sateesh Kumar ; Alluri, Rohit ; Lakkala, Preethi ; Munnangi, Siva Ram ; Narala, Nagarjuna

This study reports the development and optimization of a pH-modulating vaginal film fabricated via solvent-free direct powder extrusion 3D printing for localized sperm immobilization. The formulation incorporates lactic acid (90 mg), citric acid (50 mg), and potassium bitartrate (20 mg), the same clinically validated actives present in the Food and Drug Administration (FDA) - approved contraceptive gel Phexxi®. These actives were reformulated within a flexible polyethylene oxide matrix to enable a convenient, applicator-free solid dosage form. A Quality by Design (QbD) framework employing a four-factor, three-level Box-Behnken design was implemented to optimize independent variables like plasticizer concentration, printing temperature, extrusion pressure, and printing speed against dependent variables like disintegration time, film elasticity, and printability. The optimized film disintegrated within 84 s in simulated vaginal fluid and maintained vaginal pH within 3.5-4.0 over two hours under a six-fold excess of seminal fluid simulant, consistent with the acidic threshold required for sperm immobilization. FTIR and ¹H NMR confirmed chemical stability post-processing, and three months of accelerated stability testing verified preservation of mechanical and functional performance. These findings establish a QbD-guided, on-demand vaginal film as a promising hormone-free contraceptive platform that combines a clinically validated pH-modulating composition with a convenient applicator-free solid dosage form.

2026-05-01·NEURO-ONCOLOGY

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma

Article

作者: Malani, Rachna ; Schaff, Lauren R ; Francis, Jasmine H ; Reiner, Anne S ; DeAngelis, Lisa M ; Yang, Kerina ; Quinn, Lilian ; Grommes, Christian ; Gonzalez, Ashley ; Kaley, Thomas J ; Panageas, Katherine S ; Young, Robert J ; Gavrilovic, Igor T ; Tobin, Josey ; Stone, Jacqueline ; Emadi-Paramkouhi, Laleh ; Rodriguez, Alyssa ; Kaluski, Maya ; Pentsova, Elena ; Mellinghoff, Ingo K

Abstract:

Background:

High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL). Only ∼60% of patients achieve a complete response to first-line therapy with frequent relapses. The Bruton’s tyrosine kinase inhibitor ibrutinib has shown promising antitumor activity in recurrent/refractory PCNSL.

Methods:

The goal of the current single-center phase 2 trial was to explore whether the addition of ibrutinib to the combination of rituximab, methotrexate, procarbazine, and vincristine (R-MVP/i) increases complete response rate (CCR).

Results:

Thirty newly diagnosed PCNSLs were enrolled; median age 69 (range 41-79), median Eastern Cooperative Oncology Group (ECOG) = 1. Twenty-nine patients completed R-MVP/i, 1 withdrew consent after 2 cycles. A complete response (CR)/complete response unconfirmed (CRu) was achieved in 29 patients and a partial response in 1 for a CRR of 29/30 (97%, 95% CI: 83.3%, 99.8%). Treatment was well tolerated with no grade 5 toxicity observed. Eight patients experienced 13 grade 4 toxicities (lymphopenia [n = 3], neutropenia [n = 4], thrombocytopenia [n = 3], and white cell count decrease [n = 3]). The most common toxicities were thrombocytopenia, anemia, lymphopenia, and liver enzyme elevations. No Aspergillus or Pneumocystis infections occurred. No refractory disease was observed. For the 29 patients completing the trial, 19 received consolidation with cytarabine (Ara-C), 8 autologous stem cell transplant, 1 rituximab maintenance, and 1 was observed without maintenance or consolidation. At a median follow-up of 25.1 months (range 3.3-49.2), the median progression-free (PFS) and overall survival were not reached with a 2-year PFS of 84.2% (95% CI: 62.7%-93.9%).

Conclusions:

R-MVP/i was well tolerated and associated with excellent disease control and survival.

2026-04-01·Cancer Medicine

Comparative Outcomes of Consolidation Strategies After R‐ MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System

Article

作者: Ji Yun Lee ; Chul-Kee Park ; Keun-Yong Eom ; Sang-A Kim ; Jeong-Ok Lee ; Jung Sun Kim ; Chae-Yong Kim ; Tae Min Kim ; Dae Seog Heo ; Joo Ho Lee

ABSTRACT:

Background:

The optimal consolidation strategy following high‐dose methotrexate (MTX)–based induction in primary central nervous system lymphoma (PCNSL) remains controversial. This study compared real‐world outcomes of different consolidation modalities in patients responsive to rituximab, MTX, vincristine, and procarbazine (R‐MVP) induction chemotherapy.

Methods:

We retrospectively analyzed 296 newly diagnosed PCNSL patients treated with R‐MVP between 2008 and 2023. Among 290 evaluable patients, the overall response rate (ORR) was assessed, and survival outcomes were evaluated by Kaplan–Meier and Cox regression analyses. Propensity score matching (PSM) was performed to compare autologous stem‐cell transplantation (ASCT) and whole‐brain radiotherapy (WBRT).

Results:

The ORR was 89.7%, with 71.7% achieving complete response (CR) or complete response unconfirmed (CRu) and 17.9% partial response (PR). Of 260 responders, 190 received consolidation: WBRT (40.8%), ASCT (20.0%), or non‐myelosuppressive chemotherapy (NMC; 12.3%). After a median follow‐up of 45.3 months, median progression‐free survival (PFS) and overall survival (OS) for responders were 65.8 (95% CI 50.7–80.8) and 84.6 months (95% CI 66.5–102.7), respectively. ASCT yielded the most favorable survival (median PFS not reached), followed by WBRT (70.8 months), whereas NMC and no‐consolidation groups showed significantly inferior PFS (22.9 and 40.1 months, p < 0.001). OS showed a similar trend ( p = 0.006). On multivariable analysis, elevated LDH and consolidation type were independent predictors of PFS, whereas age and consolidation type were significant prognostic factors for OS. In the PSM cohort (ASCT vs. WBRT, n = 52 each), median PFS was not reached for ASCT versus 90.0 months for WBRT ( p = 0.050); OS was not reached versus 97.9 months ( p = 0.160).

Conclusions:

ASCT was associated with the most durable survival among consolidation strategies after R‐MVP induction. These findings, derived from a large real‐world, multi‐institutional cohort, support ASCT as the preferred consolidation for eligible patients while underscoring the heterogeneity of current practice and the need for prospective validation.

项与 L-乳酸/柠檬酸/酒石酸氢钾相关的新闻（医药）

2025-10-20

·PRNewswire

Evofem Announces Voting Results from Special Meeting of Stockholders

-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ: ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised its rights to terminate the Merger Agreement. "With the outcome of this meeting, we are pivoting to focus our efforts on regaining a national listing for Evofem's stock and securing capital to catalyze our growth trajectory and better position us to deliver sustainable positive EBITDA in 2027," said Saundra Pelletier, CEO of Evofem Biosciences. "We are grateful to Aditxt for its support of Evofem and our mission through its meaningful investments, and we look forward to a fruitful collaboration to commercialize the Mitomic™ diagnostic tests for women's health conditions , including endometriosis and ovarian cancer, under our September 2024 agreement." Evofem is taking steps to execute its long-term growth strategy with emphasis on delivering value for investors and the women and healthcare providers who rely on its products for their sexual health needs. The Company commercializes two FDA-approved sexual health products: PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel for hormone-free, on-demand contraception, and SOLOSEC® (secnidazole) 2 g oral granules, a single dose oral 5-nitroimidazole drug indicated for the treatment of bacterial vaginosis (BV) in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. 2024 was its fourth consecutive year of net sales growth. About Evofem Biosciences Evofem Biosciences, Inc. is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products: PHEXXI® (lactic acid, citric acid, and potassium bitartrate) is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2 g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include those related to Evofem's strategic plans, including regaining a national listing for its stock, securing capital to catalyze its growth trajectory, and the anticipated achievement of sustainable positive EBITDA and timing thereof as well as the anticipated regulatory clearance of the Mitomic diagnostic tests and expected collaboration with Aditxt to commercialize them. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, without limitation: the potential impacts on the Company's business, results of operations, and financial condition as a result of the termination of the Merger Agreement and Merger or any challenges to such termination; litigation that may arise from or in connection with the now-terminated Merger Agreement, if any; the risk that any announcements relating to the terminated Merger could have adverse effects on the market price of the Company's common shares; the Company's ability to repay its senior debt holders; the Company's ability to pay the significant costs, expenses, and fees for professional services and other costs in connection with the terminated Merger; the risk that the terminated Merger could have an adverse effect on the ability of the Company to retain and maintain relationships with customers, suppliers, and other business partners; the Company's success in regaining a national listing for its stock; its success in securing sufficient capital to catalyze its growth trajectory; the Company's anticipated sales growth; its ability to attract and retain sales representatives and other personnel; the ability of the commercial organization to deliver the anticipated results; and other factors that are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Contact Amy Raskopf Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

并购上市批准

2025-10-01

·PRNewswire

Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

— First ex-U.S. Regulatory Filing for SOLSOEC® — — Pharma 1 Targets 1H 2026 Launch in UAE for SOLOSEC® to Treat Bacterial Vaginosis and Trichomoniasis, leveraging its commercial infrastructure and expertise in women's health — SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem, or the Company) (OTCID: EVFM) announced today that its licensee for the Middle East and North Africa (MENA), private Emirati health care company Pharma 1, has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval to commercialize SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral treatment for two common sexual health conditions. "Bacterial vaginosis (BV) and trichomoniasis affect millions of people in the member states of the Gulf Cooperation Council (GCC). SOLOSEC treats both of these sexual health conditions with just one oral dose. With the submission complete, we are developing our commercial strategy and look forward to launching this important product in the UAE as quickly as possible following approval," said Abdulwahab Atfah, CEO of Pharma 1 Drug Store. "We expect SOLOSEC will be extremely well received in the medical community, among women with BV, and by men and women afflicted with trichomoniasis seeking a convenient, single-dose oral treatment." "This filing is an important milestone towards the commercialization of SOLOSEC outside the U.S. and to further expand and diversify our revenue stream," said Saundra Pelletier, CEO of Evofem. "We look forward to receiving Pharma 1's initial order shortly after approval to support the launch in the UAE." Pharma 1 holds the exclusive commercialization rights for SOLOSEC® and PHEXXI® (lactic acid, citric acid and potassium bitartrate) in the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar and certain other countries in the licensed Territory. In addition to obtaining and maintaining any regulatory approvals required to market and sell the products, Pharma 1 will handle all aspects of distribution, sales and marketing, pharmacovigilance, and all other commercial functions in these countries. Since its inception in 2019, Pharma 1 has continued to successfully execute its mission of offering practical solutions to fulfill health care needs based on scientific studies and accurate surveys. The company's success reflects its substantial expertise, scientific approach, and agility to adapt to the very dynamic and growing market in the GCC. SOLOSEC®, a single dose oral 5-nitroimidazole drug, is FDA-approved and indicated for the treatment of two sexual health diseases: Bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older Trichomonas vaginalis, a common sexually transmitted infection (STI), in people 12 years of age and older SOLOSEC® provides a complete course of therapy in just one dose. Studies in the Middle East and North Africa (MENA) region have reported BV prevalence ranging from 25% to 41%. A systematic review and meta-analysis of global BV prevalence among reproductive-aged women in the general population found that one in four women in MENA have BV1. In the UAE alone, this represents between 1.0 million and 1.7 million women. Despite the availability of anti-infectives approved to treat Trichomonas vaginalis, the parasite that causes trichomoniasis, in 2020 the WHO estimated 156.3 million new cases of trichomoniasis worldwide: 73.7 million in females and 82.6 million in males.3 Undiagnosed infections and lack of compliance with multi-day treatment regimens are critical contributing factors. A meta-analysis of evidence sourced from 263 international, regional, and national databases found that MENA has a substantial trichomoniasis prevalence, with approximately 4.7% of women in the general population affected by this sexually transmitted infection (STI).2 Trichomoniasis was more common in intermediate- and high-risk populations (17.2% and 10.3%, respectively) and among symptomatic women (13.9%). About Bacterial Vaginosis Bacterial vaginosis (BV), the most common cause of vaginal discharge in reproductive-age women1, is associated with multiple consequential adverse outcomes including an increased risk of adverse birth outcomes, acquisition of human immunodeficiency virus and other STIs, pelvic inflammatory disease, and a high incidence of symptomatic recurrence.4 A study published in the New England Journal of Medicine in 2025 provided evidence that BV is in fact an STI.5 About Trichomoniasis Trichomoniasis (or "Trich") is an STI caused by infection with Trichomonas vaginalis, a protozoan parasite. It is the most common nonviral STI globally, affecting an estimated 156 million men and women worldwide. 3 The CDC notes that up to 70% of people infected with Trich are unaware that they are infected and may unwittingly pass the parasite to sexual partners.6 Untreated infections might last from months to years. In women, Trich can cause a foul-smelling vaginal discharge, genital itching, and pain with urination or sex. Trich is also associated with an increased risk for cervical cancer, infertility, HIV acquisition, and, among women with HIV infection, pelvic inflammatory disease (PID). Pregnant women who have Trich might be at higher risk of delivering their babies prematurely. Men who have Trich typically have no symptoms, however when men do have symptoms these may include itching or irritation inside the penis, burning with urination or after ejaculation and discharge from the penis.2 About Evofem Biosciences Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products. PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. About Pharma 1 Pharma 1 Drug Store is an Emirati company dedicated to providing practical solutions, backed by scientific studies and accurate surveys, that cater to the ever-evolving healthcare needs of people in the GCC and support development of a healthier community. Pharma 1 are agents to a growing number of pharmaceutical companies, with a variety of commercial products and medications in process with the Ministry of Health and Prevention. Learn more at . Sources Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019 May;46(5):304-311. doi: 10.1097/OLQ.0000000000000972. PMID: 30624309. Harfouche M, Gherbi WS, Alareeki A, Alaama AS, Hermez JG, Smolak A, Abu-Raddad LJ. Epidemiology of Trichomonas vaginalis infection in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions. EBioMedicine. 2024 Aug;106:105250. doi: 10.1016/j.ebiom.2024.105250. Epub 2024 Jul 17. PMID: 39024899; PMCID: PMC11286989. World Health Organization. Trichomoniasis Fact Sheet. 2024 November 25. Accessed 2025 May 15 via . Muzny CA, Balkus J, Mitchell C, et al. Diagnosis and management of bacterial vaginosis: summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention sexually transmitted infections treatment guidelines. Clin Infect Dis. 2022;74:Suppl_2:S144-S151. Vodstrcil L, Plummer E, Fairley C, Hocking, Law M, Petoumenos M, Bateson D et al. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2025; 392:947-957. DOI: 10.1056/NEJMoa2405404. U.S. Center for Disease Control. Sexually Transmitted Diseases: About Trichomoniasis. Accessed 2025 May 15 via . Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to expected timing of the review by MOHAP of the SOLOSEC® dossier and outcome thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 14, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Connect With Us Media [email protected] Investors and Potential Partners Amy Raskopf, Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 Join the Dialogue SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-09-26

·PRNewswire

Evofem Biosciences Honors World Contraception Day

SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater. Evofem's mission has always centered on challenging the status quo in women's health — offering groundbreaking choices where few exist and leading conversations others avoid. With products like PHEXXI® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC® (secnidazole) 2g oral granules, a single-dose oral treatment for bacterial vaginosis and trichomoniasis, Evofem is working to ensure women have more tools to safeguard their reproductive and sexual health. "World Contraception Day is about making sure every person has access to safe, effective, and affordable choices," said Saundra Pelletier, CEO of Evofem Biosciences. "Let's be honest – most women do not have sex every day. They deserve a contraceptive option that enables them to have sex on demand and PHEXXI makes this possible. We are proud to offer this non-hormonal innovative solution to the women who have suffered side effects from synthetic hormones in birth control; cancer thrivers; breast feeding mothers; and women who simply do not want to 'over-medicate' themselves with hormonal contraception." In addition to commercializing science-backed, FDA-approved products, Evofem is committed to awareness and education campaigns that confront stigma directly. The Company's international " Say Vagina" initiative has reached millions by challenging censorship, dismantling shame surrounding female anatomy, and improving health education. Through this campaign, Evofem is turning awareness into action. As the Company looks ahead, Evofem remains dedicated to breaking barriers, expanding global access, and ensuring that women's health continues to receive the investment and innovation it deserves. On World Contraception Day, Evofem reaffirms its vision: a world where reproductive health options are celebrated, supported, and accessible to all. About Evofem Biosciences Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products. PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Connect With Us Media [email protected] Investors and Potential Partners Amy Raskopf, Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 Join the Dialogue SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

100 项与 L-乳酸/柠檬酸/酒石酸氢钾相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G02BB	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
避孕	美国	Evofem, Inc.	2020-05-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
沙眼衣原体感染	临床3期	美国	Evofem, Inc.	2020-10-15
淋病	临床3期	美国	Evofem, Inc.	2020-10-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04553068 (EVOGUARD, CTgov)	临床3期	淋病 \| 沙眼衣原体感染	1,892	EVO100 (EVO100 Gel)	觸築夢鏇網憲淵範壓積 = 衊積範艱顧繭遞範願鹽蓋餘觸顧衊鹹壓窪鏇淵 (糧膚淵築獵艱鹹鏇鬱齋, 艱衊選製醖淵齋獵醖築 ~ 鹽鬱簾衊築製網壓觸願) 更多	-	2024-01-30
				Placebo (Placebo Gel)	觸築夢鏇網憲淵範壓積 = 網糧製繭艱鹹選顧窪鑰蓋餘觸顧衊鹹壓窪鏇淵 (糧膚淵築獵艱鹹鏇鬱齋, 糧願憲遞鏇選獵遞壓鑰 ~ 衊齋鏇蓋蓋艱觸艱餘衊) 更多
NCT04553068 (EVOGUARD, PRNewswire) 人工标引	临床3期	衣原体感染 \| 淋病	1,903	EVO100	餘艱積淵淵築鹽積選顧(獵廠膚憲獵繭遞觸範糧) = Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints. 窪獵觸選醖齋襯廠繭製 (獵製糧繭獵糧築積餘顧 )	不佳	2022-10-11
				Placebo
NCT03107377 (AMPREVENCE, Pubmed \| Am J Obstet Gynecol)	临床2/3期	感染	860	EVO100	醖獵鬱衊選鹹願膚鹹壓(繭鹹選淵壓蓋蓋艱鏇窪) = 4.6% [18/388] 遞醖鬱構淵網糧顧鏇選 (選繭選繭廠淵鬱選願壓 ) 更多	积极	2021-03-08
				Placebo
NCT03107377 (AMPREVENCE, CTgov)	临床2/3期	沙眼衣原体感染	860	EVO100 (EVO100)	淵繭壓壓範襯願夢製鹹 = 淵鏇餘淵積襯夢廠餘積遞襯蓋齋壓構窪襯觸餘 (壓繭獵膚衊遞衊願鹽製, 遞鬱選餘憲窪鏇構齋觸 ~ 憲淵獵鏇淵鏇餘顧膚範) 更多	-	2020-08-12
				Placebo (Placebo)	淵繭壓壓範襯願夢製鹹 = 艱願簾廠製鏇膚築襯齋遞襯蓋齋壓構窪襯觸餘 (壓繭獵膚衊遞衊願鹽製, 鬱構窪鏇壓衊夢獵網憲 ~ 築築鏇壓築製衊夢鹽憲) 更多